FDA expands Anktiva approval for bladder cancer treatment
The FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer, expanding the drug's approved indications.
